Healthy
Conditions
Brief summary
Study to compare the bioavailable fraction of epinastine and pseudoephedrine when administered as a fixed dose combination in tablet form (new pharmaceutical formulation), with that obtained with each of these drugs when administered separately to healthy volunteers.
Interventions
Sponsors
Boehringer Ingelheim
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
21 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy volunteers of both sexes aged between 21 and 45 years * Non-smoking volunteers * Volunteers willing to abstain from alcohol * The volunteers will have to have suspended any drug treatment at least two weeks prior to the start of the study * Informed consent in writing, signed in time for the start of the study
Exclusion criteria
* Women who are pregnant, breast-feeding or receiving hormonal contraceptives * Volunteers who require drug treatment of any kind of a chronic nature or due to a known addiction * Volunteers who have taken part in another clinical trial during the preceding four weeks * Volunteers who have to begin treatment incompatible with this one during the period of the present study (systemic anaesthetics by inhalation, antihypertensives or diuretics used as antihypertensives, beta-adrenergic blockers, CNS (central nervous system) stimulants, digitalis, glycosides, levodopa, monoamine oxidase inhibitors, nitrates, rauwolfia alkaloids, thyroid hormone sympathomimetics) * Volunteers who do not observe the fasting stipulated in the study or who do not satisfy its requirements with respect to avoiding the ingestion of coffee, tea, cola drinks, etc. during the 24 hours prior to the study * Volunteers with a history of hepatic or renal disease and disorders of psychiatric origin * A history of allergy or intolerance with respect to epinastine or pseudoephedrine * Volunteers who are intolerant of other sympathomimetics (e.g. salbutamol, amphetamine, ephedrine, etc.) * Non-cooperative volunteers * Previous participation in this study * Histories of cardiovascular disease, ischaemic heart disease, hypertension, diabetes mellitus, glaucoma, hyperthyroidism, prostatic hypertrophy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Area under the curve (AUC) of the analyte in plasma | Pre-dose, 15, 30, 45 minutes and 1, 2, 4, 6, 8, 12, 24 hours post-dose |
| Index of the absorption rate Cpmax/AUCt (Peak plasma concentration/Area under the curve from zero to 24 hours) | Pre-dose, 15, 30, 45 minutes and 1, 2, 4, 6, 8, 12, 24 hours post-dose |
Secondary
| Measure | Time frame |
|---|---|
| T1/2 (Drug half-life) | Pre-dose, 15, 30, 45 minutes and 1, 2, 4, 6, 8, 12, 24 hours post-dose |
| Number of patients with adverse events | up to 15 days |
| Peak plasma concentration (Cpmax) | Pre-dose, 15, 30, 45 minutes and 1, 2, 4, 6, 8, 12, 24 hours post-dose |
| Number of patients with clinically significant changes in vital signs | Baseline, day 1, 8, 15 |
| Number of withdrawals and discontinuations due to safety reasons | up to 15 days |
| Tmax (Time to reach Cpmax) | Pre-dose, 15, 30, 45 minutes and 1, 2, 4, 6, 8, 12, 24 hours post-dose |
Outcome results
None listed